ATHOS-3

Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018. The Study And The Results The full data from the Phase III study,...

The capriciousness associated with the biotech space is in the forefront once again with the near doubling in the shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) on Monday. The shares were on a high in reaction to positive trial results of its treatment option for hypotension. The...